The CAR-T treatment Kymriah (Tisagenlecleucel), which is considered the hope of terminal blood cancer patients, was launched in Korea after 4 years, but there are problems to be solved.

Kymriah is treated in a completely different way from existing medicines, so it is not easy to calculate the drug price, and at a price of ₩500 million, there are many concerns about applying benefits.

Kymriah is the first CAR-T treatment in Korea and is currently the most expensive drug. Indications are diffuse large B-cell lymphoma in adults and B-cell acute lymphocytic leukemia in children and young adults. In both cases, terminal patients who are ineffective after two or more treatments, recurren